Fortress Biotech, Inc. (FBIO) Receives Consensus Rating of “Buy” from Analysts
Shares of Fortress Biotech, Inc. (NASDAQ:FBIO) have been assigned an average recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $10.50.
Several analysts recently commented on FBIO shares. HC Wainwright set a $11.00 target price on Fortress Biotech and gave the stock a “buy” rating in a report on Tuesday, July 11th. Zacks Investment Research raised Fortress Biotech from a “sell” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Monday, May 15th. FBR & Co reaffirmed a “buy” rating and set a $11.00 target price on shares of Fortress Biotech in a report on Friday, May 12th. Rodman & Renshaw started coverage on Fortress Biotech in a report on Tuesday, July 11th. They set a “buy” rating and a $11.00 target price on the stock. Finally, ValuEngine raised Fortress Biotech from a “sell” rating to a “hold” rating in a report on Wednesday, June 7th.
A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in shares of Fortress Biotech by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 110,061 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 5,170 shares during the last quarter. ClariVest Asset Management LLC raised its stake in shares of Fortress Biotech by 1.0% in the first quarter. ClariVest Asset Management LLC now owns 161,519 shares of the biopharmaceutical company’s stock valued at $598,000 after buying an additional 1,600 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Fortress Biotech by 3.2% in the first quarter. Geode Capital Management LLC now owns 288,566 shares of the biopharmaceutical company’s stock valued at $1,067,000 after buying an additional 8,958 shares during the last quarter. KCG Holdings Inc. acquired a new stake in shares of Fortress Biotech during the first quarter valued at approximately $188,000. Finally, Abner Herrman & Brock LLC acquired a new stake in shares of Fortress Biotech during the second quarter valued at approximately $493,000. 13.12% of the stock is currently owned by institutional investors.
Shares of Fortress Biotech (NASDAQ:FBIO) opened at 4.14 on Friday. Fortress Biotech has a one year low of $1.88 and a one year high of $5.07. The company’s 50 day moving average is $4.65 and its 200 day moving average is $3.69. The company’s market capitalization is $208.37 million.
Fortress Biotech (NASDAQ:FBIO) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.78 million for the quarter, compared to analyst estimates of $47.04 million. Fortress Biotech had a negative return on equity of 63.99% and a negative net margin of 269.14%. Equities research analysts predict that Fortress Biotech will post ($1.20) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/05/fortress-biotech-inc-fbio-receives-consensus-rating-of-buy-from-analysts.html.
About Fortress Biotech
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.